UNITED STATES OF AMERICA —Regenerative medicine manufacturer BioStem Technologies, Inc. has entered into a $40 million committed equity facility agreement with Roth Principal Investments, LLC, an affiliate of CR Financial Holdings. Under the terms of the private placement structure, the company holds the option, but not the obligation, to issue and sell common stock to the investor over time following the approval of an SEC resale registration statement. Capital issuances under the agreement remain bound by standard Nasdaq Exchange Cap limits capping unapproved issuances at 19.99% of outstanding shares unless specific pricing parameters or shareholder approvals are met.
Based in Pompano Beach, Florida, BioStem Technologies develops, manufactures, and commercializes perinatal tissue allografts processed through proprietary technologies to optimize tissue preservation for specialized clinical treatments.
This flexible financing structure offers BioStem opportunistic liquidity to reinforce its working capital base and fund operational expansion without forcing immediate equity dilution. By maintaining full discretion over the timing and volume of stock issuances, the company can align capital drawdowns with favorable market conditions and key operational milestones.
Developments of this nature highlight the growing reliance on tailored equity facilities among commercial-stage biotechnology firms seeking non-restrictive growth capital. For industry stakeholders and institutional investors, the facility provides BioStem with enhanced financial flexibility to scale its advanced tissue-processing operations, navigate market volatility, and expand its commercial footprint within the regenerative healthcare market.
